Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Lupus

    Current Location

    Search
    Lupus
    Show Map
    Map View
    Your Location

    Popular Searches

    By Condition

    Depression Clinical Trials

    Anxiety Clinical Trials

    Schizophrenia Clinical Trials

    ADHD Clinical Trials

    Bipolar Disorder Clinical Trials

    Multiple Sclerosis Clinical Trials

    Autism Clinical Trials

    Treatment Resistant Depression Clinical Trials

    Borderline Personality Disorder Clinical Trials

    Social Anxiety Disorder Clinical Trials

    Parkinson's Disease Clinical Trials

    Alzheimer's Disease Clinical Trials

    By Location

    Clinical Trials in California

    Clinical Trials in Florida

    Clinical Trials in Texas

    Clinical Trials in New York

    Clinical Trials in Ohio

    Clinical Trials in Illinois

    Clinical Trials in Pennsylvania

    Clinical Trials in Michigan

    Clinical Trials in North Carolina

    Clinical Trials in Massachusetts

    Clinical Trials in Missouri

    Clinical Trials in Minnesota

    Other People Viewed

    By Subject

    Top Lupus Nephritis Clinical Trials

    Top Systemic Lupus Erythematosus Clinical Trials

    15 Polymyositis Trials Near You

    74 Arthritis Trials near Irvine, CA

    57 Clinical Trials near Minnesota

    Top Amyloidosis Clinical Trials

    Top Hypertrophy Clinical Trials

    Top Breast Clinical Trials

    Top Ocd Clinical Trials

    Top Vitiligo Clinical Trials

    Top Osteopenia Clinical Trials

    Top Mesothelioma Clinical Trials

    By Trial

    Belimumab + Voclosporin for Lupus Nephritis

    Obexelimab for Lupus

    Cenerimod for Systemic Lupus Erythematosus

    Cenerimod for Systemic Lupus Erythematosus

    Mobile App Intervention for Childhood-Onset Lupus

    Yoga-Based Coaching for Lupus

    Belimumab for Pediatric Lupus

    Ianalumab for Lupus

    NKX019 + Cyclophosphamide for Lupus Nephritis

    Obinutuzumab for Lupus Nephritis

    VAY736 + CFZ533 for Lupus

    DS-7011a for Lupus

    Related Searches

    Top Treatment for Lenalidomide Clinical Trials

    Top Ovarian-cancer Clinical Trials

    AI-Generated Instructions for Patient Education

    Exercise + Mindfulness for Bladder Cancer

    Total Marrow Irradiation for Acute Myeloid Leukemia

    PS-OCT Eye Scan for Retinal Imaging

    Trontinemab for Alzheimer's Disease

    Travoprost Implant for Glaucoma

    Proton Therapy vs. Photon Radiation for Prostate Cancer

    Genetic Screening and MRI for Prostate Cancer

    Roadmap to Parenthood Tool for Family Planning After Cancer

    Vitamin D Supplements for Neuropathic Pain

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      73 Lupus Trials Near You

      Power is an online platform that helps thousands of Lupus patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Anifrolumab for Lupus

      Columbus, Ohio
      A Study to evaluate the PK, PD, efficacy, and safety of Anifrolumab in children with moderate to severe active SLE
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:5 - 17

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis B, Hepatitis C, Others
      Must Not Be Taking:Cytotoxic B-cell Depleters

      100 Participants Needed

      Obinutuzumab for Lupus

      Columbus, Ohio
      This trial is testing a medication called obinutuzumab in people with active lupus who have specific antibodies in their blood. These patients are already on standard treatments but need more help. The medication works by reducing harmful immune cells that cause inflammation and damage.
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Renal Disease, Infection, Others
      Must Be Taking:Oral Corticosteroids, Antimalarials

      303 Participants Needed

      M5049 for Lupus

      Columbus, Ohio
      This trial involves taking a pill called M5049. It targets patients with specific types of lupus who have already been treated for several months. The goal is to check if the pill is safe and works well over a longer time.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Severe Infections, Psychiatric Conditions, Others

      379 Participants Needed

      N-acetylcysteine for Lupus

      Columbus, Ohio
      Systemic lupus erythematosus (SLE) is a chronic inflammatory disease which often has debilitating and potentially life-threatening consequences. The cause of SLE is unknown and current therapies lack specificity and carry significant side-effects. We previously discovered the depletion of glutathione in lymphocytes of patients with SLE and associated this metabolic change with the elevation of the mitochondrial transmembrane potential. This study will titrate to tolerance during an initial 3 month open label period and then subjects will be randomized to one of 2 arms. It was determined by statistical analysis that each group must have 105 subjects. All subjects will be enrolled and evaluated for tolerance of NAC between dosages of 2.4 g/day and 4.8 g/day for 3 months. After A 3-month open-label dose-titration phase, SLE subjects will be randomized into 2 groups of 105 subjects either to continue the tolerated dosage of NAC or switched to equal number of placebo capsules. There will be up to seven study visits per SLE subject, including the screening and wash out visits. Visits 2-6 will be scheduled three months apart. The study will last 13 months with the wash-out visit. Each subject will donate approximately 100 ml of blood for biomarker studies at each visit. Healthy control subjects will donate blood at the same time. They will be matched to the SLE subjects by gender, age within 10 years, and ethnicity. Their blood will be used as reference for biomarker assays. There is a consent form required to participate in the phase II study.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Acute SLE Flare, Pregnancy, Serious Comorbidities, Active Infections, Others
      Must Be Taking:Immunosuppressants, Antimalarials, Corticosteroids

      290 Participants Needed

      Felzartamab for Lupus Nephritis

      Columbus, Ohio
      In this study, researchers will learn more about the use of felzartamab in people with active lupus nephritis, also known as LN. In people with LN, antibodies build up in the glomeruli of the kidneys. Antibodies are proteins in the blood used by the immune system to fight infection. Glomeruli are small filters that remove waste and extra fluid from the blood. This buildup leads to inflammation and damage to the kidneys. Kidney damage can lead to too much protein and blood leaking into the urine. High levels of protein in the urine, called proteinuria, are common in people with LN. Symptoms of LN can include fever, swelling in the legs and body, and high blood pressure. If left untreated, LN can eventually lead to kidney failure. In this study, researchers will learn more about how a study drug called felzartamab affects people with LN. Felzartamab is a monoclonal antibody, which means it is an antibody made in a laboratory. Felzartamab can target immune cells that produce antibodies, helping to lower their buildup in the kidneys. The main goal of this study is to learn more about the safety of felzartamab and how it works in the body of people with LN who are taking standard of care. This will help researchers decide if they should do more studies with felzartamab in people with LN. Standard of care is the usual treatment or care given to patients for a disease, as prescribed by their doctor. The main question researchers want to answer in this study are: • How many participants had adverse events during the study? An adverse event is a health problem that may or may not be caused by the study drug. It can happen during a clinical study or within a certain amount of time after the study has ended. Researchers will also learn more about: * How much felzartamab affects proteinuria and the level of creatinine in the urine. Creatinine is a protein that is released into the blood from normal muscle wear and tear. Its levels can help doctors understand how well your kidneys are working. * How many participants have a complete response. A complete response means that their urine protein levels decrease to a low level, and their kidney function stays stable. * How many participants have a 50% decrease in the level of protein and creatinine in their urine. * How much felzartamab affects the participants' lupus-related blood tests. * How the body processes felzartamab. * How many participants develop antibodies against felzartamab in the blood. This study will be done as follows: * Participants will be screened to check if they can join the study. The screening period will be up to 42 days. * Throughout the study, all participants will continue taking their standard of care, as prescribed by their doctor. * There are 2 parts in this study. In both parts, participants will receive felzartamab through an intravenous infusion, also known as an IV. This means it is being given into a vein. * In Part 1, participants will have up to 14 visits to their study research center. In Part 2, participants may have up to 15 visits. * Each participant will be in the study for about 2 years.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Rapidly Progressive Glomerulonephritis, Dialysis, Kidney Transplant, Others

      20 Participants Needed

      Afimetoran for Lupus

      Columbus, Ohio
      This trial is testing a new medication called Afimetoran to help people with active Systemic Lupus Erythematosus (SLE). The goal is to see if it can safely reduce symptoms by calming down the immune system. The study will also provide data on its effectiveness and safety over time.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Severe Lupus Nephritis, Neuropsychiatric Lupus, Mixed Connective Tissue Disease, Antiphospholipid Syndrome

      268 Participants Needed

      SYNCAR-001 + STK-009 for Lupus

      Columbus, Ohio
      This is a phase 1 study of SYNCAR-001 + STK-009 in patients with severe, refractory systemic autoimmune rheumatic disease.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:CNS Manifestations, Gene Therapy, Dialysis, Others

      48 Participants Needed

      GSK4527363 for Lupus

      Columbus, Ohio
      This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of GSK4527363 in healthy participants (Part A), participants with active SLE (Part B), and healthy participants of Chinese and Japanese descent (Part C)
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular, Respiratory, Hepatitis, HIV, Others
      Must Not Be Taking:Antibiotics, Antivirals

      142 Participants Needed

      BAFF CAR-T Cells for Lupus

      Columbus, Ohio
      This phase 1 study seeks to examine the safety and recommended phase 2 dose (RP2D) of BAFF-ligand CAR-T cells (LMY-920) in adult patients with refractory systemic lupus erythematosus (SLE). It is hypothesized that BAFF CAR-T cells will be safe and will improve SLE disease activity scores.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Neuropsychiatric Lupus, Active Infection, HIV, Genetic Syndromes, Others
      Must Be Taking:Corticosteroids, Hydroxychloroquine

      18 Participants Needed

      CUG252 for Lupus

      Columbus, Ohio
      This trial tests CUG252, a new medicine for people with Systemic Lupus Erythematosus (SLE). It aims to enhance beneficial immune cells while reducing unwanted immune activity. The study will check its safety and effectiveness over time.

      Trial Details

      Trial Status:Active Not Recruiting
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      40 Participants Needed

      Obinutuzumab + Standard Therapy for Lupus Nephritis

      Columbus, Ohio
      This trial tests if adding obinutuzumab to standard treatments is safe and effective for patients with severe kidney inflammation from lupus. It helps the immune system remove harmful cells and has shown better results in kidney health compared to standard treatments alone.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Severe Renal Impairment, Others
      Must Be Taking:Mycophenolate Mofetil, Corticosteroids

      271 Participants Needed

      Belimumab + Voclosporin for Lupus Nephritis

      Columbus, Ohio
      This is a Phase IV, open-label, randomized trial to determine whether the combination of Belimumab (BEL) and Voclosporin (VCS), plus background therapy with Mycophenolate Mofetil (MMF), improves the proportion of patients with proliferative lupus nephritis achieving complete renal response (CRR) compared to proportion of patients achieving CRR from recent clinical trials. This protocol will additionally determine whether combination therapy using Belimumab (BEL) and Voclosporin (VCS) facilitates rapid discontinuation of MMF.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Dialysis, HIV, Malignancy, Others
      Must Be Taking:Belimumab

      30 Participants Needed

      Mycophenolate Mofetil for Pediatric Lupus Nephritis

      Columbus, Ohio
      The study is a 1-year 2-part double-blinded placebo controlled 2-arm clinical trial. Treatment arms are (1) MMF dosed as per body-surface area (MMFBSA; 600mg/m2 body surface area per dose about every 12 hours) and (2) pharmacokinetically-guided precision-dosing of MMF (MMFPK; MMF dosed twice daily to achieve an area under the concentration-time curve (AUC0-12h) of MPA \>60-70 mg\*h/L. The study goal is to determine the safety and efficacy of MMFPK compared to MMFBSA for the treatment of proliferative LN in subjects 8 to \<21 years.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:8 - 20

      Key Eligibility Criteria

      Disqualifiers:Severe Hepatic, HIV, Hepatitis B, Others
      Must Be Taking:MMF

      105 Participants Needed

      CAR T-Cell Therapy for Lupus Nephritis

      Columbus, Ohio
      This trial is testing a new treatment that uses modified immune cells to target and destroy harmful cells in adults with severe kidney inflammation from lupus that doesn't respond to usual treatments.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Hepatitis, HIV, Stroke, Seizure, Others

      6 Participants Needed

      VIB4920 for Lupus Nephritis

      Columbus, Ohio
      This trial is testing a new drug called VIB4920, along with two other medications, MMF and prednisone, to treat kidney problems caused by lupus. The study involves people who have active lupus nephritis, a serious kidney condition. The treatment aims to reduce inflammation and calm the immune system to help improve kidney function. MMF has been established as an effective treatment for lupus nephritis, often used in combination with other medications like prednisone.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Malignancy, End Stage Renal, Transplant, Others
      Must Be Taking:Mycophenolate, Prednisone

      74 Participants Needed

      Obinutuzumab for Lupus Nephritis

      Columbus, Ohio
      This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to \<12 with LN.
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:5 - 17

      Key Eligibility Criteria

      Disqualifiers:CNS SLE, Cancer, Immunodeficiency, Others
      Must Be Taking:IV Methylprednisolone

      40 Participants Needed

      Litifilimab for Cutaneous Lupus Erythematosus

      Columbus, Ohio
      This trial is testing BIIB059, a new medicine that targets specific immune cells, in patients with skin lupus who haven't responded to standard treatments. The goal is to see if it can reduce their skin symptoms by calming down these immune cells.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Active Skin Conditions, Mixed Connective Tissue Disease, Severe Lupus Nephritis, Active Neuropsychiatric SLE, Others
      Must Not Be Taking:Intralesional Corticosteroids, Immunosuppressives

      474 Participants Needed

      Daxdilimab for Discoid Lupus

      Columbus, Ohio
      This trial tests daxdilimab, an injectable medication, in patients with severe skin lupus who haven't improved with standard treatments. The drug works by calming the immune system to reduce skin symptoms.

      Trial Details

      Trial Status:Terminated
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Cancer, Cardiac Disease, HIV, Others

      72 Participants Needed

      Deucravacitinib for Cutaneous Lupus Erythematosus

      Columbus, Ohio
      This trial is testing a new medication called deucravacitinib to help people with certain types of lupus that aren't well managed by current treatments. The medication works by calming the immune system to reduce skin damage.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Acute Cutaneous Lupus, Others
      Must Be Taking:Oral Corticosteroids, Antimalarials, Immunosuppressants

      74 Participants Needed

      CC-97540 for Severe Refractory Lupus

      Columbus, Ohio
      This trial is testing a new drug called CC-97540. It aims to help people with severe autoimmune diseases that don't get better with regular treatments. Researchers want to see if the drug is safe, how it moves through the body, and if it can improve patients' health.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Drug-induced SLE, Multiple Sclerosis, Psoriasis, Others

      270 Participants Needed

      Why Other Patients Applied

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38
      Match to a Lupus Trial

      Ravulizumab for Lupus Nephritis and IgA Nephropathy

      Columbus, Ohio
      This trial is testing the safety and effectiveness of a drug called ravulizumab, given through a vein, in patients with specific kidney diseases. The drug aims to reduce kidney damage by blocking part of the immune system.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Renal Disease, Transplant History, Others
      Must Be Taking:Renin-angiotensin Inhibitors

      123 Participants Needed

      Emapalumab for MAS in Still's Disease or Lupus

      Columbus, Ohio
      This trial is testing emapalumab, a medication that helps control an overactive immune system, in children and adults with certain immune conditions who haven't responded to high-dose steroids. The goal is to see if it is safe and effective in reducing excessive inflammation. Emapalumab is a monoclonal antibody that targets interferon-γ and was first approved for treating primary hemophagocytic lymphohistiocytosis (HLH) in patients with refractory, recurrent, or progressive disease.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:6 - 80

      Key Eligibility Criteria

      Disqualifiers:Primary HLH, Malignancy, Active Infections, Others
      Must Be Taking:Glucocorticoids

      41 Participants Needed

      ADX-097 for Immunoglobulin A Nephropathy

      Columbus, Ohio
      A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 18 Years or Older With Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), or Complement Component 3 Glomerulopathy (C3G)
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Significant Renal Disease, Uncontrolled Hypertension, Others
      Must Be Taking:RAAS Inhibitors, SGLT2 Inhibitors

      30 Participants Needed

      Nivolumab for Cancer

      Columbus, Ohio
      This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Chemotherapy, Radiotherapy, Allogeneic Transplant, Others
      Must Not Be Taking:Anticancer Investigational Agents

      300 Participants Needed

      Ianalumab for Lupus

      Dayton, Ohio
      The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:12 - 100

      Key Eligibility Criteria

      Disqualifiers:Active Infections, Hepatitis B/C, HIV, Others
      Must Be Taking:CS, Anti-malarials, DMARDs

      406 Participants Needed

      Litifilimab for Lupus

      Springboro, Ohio
      This trial is testing litifilimab, a medication for people with active systemic lupus erythematosus (SLE). It aims to see if the drug can safely reduce the immune system's attack on the body, helping to manage symptoms and prevent organ damage. Litifilimab has shown promise in reducing the number of swollen and tender joints in SLE patients.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Early Terminators, Organ-specific Lupus, Others
      Must Be Taking:Antimalarials, Steroids, Immunosuppressants

      864 Participants Needed

      Upadacitinib for Lupus

      Cincinnati, Ohio
      Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of SLE. This study is "double-blinded", which means that neither the trial participants nor the study doctors will know who will be given upadacitinib and who will be given placebo (does not contain treatment drug) . This study comprised of 4 sub studies. In Study 1 and Study 2, study doctors put the participants in 1 of the 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. Eligible participants from Study 1 and Study 2 will enter Study 3 at week 52 to receive specific doses of upadacitinib. Study 4 is a 104-week continued extension if participation is likely to provide a benefit to their SLE. Approximately 500 participants diagnosed with SLE will be enrolled in each of the Study 1 and Study 2 in approximately 320 sites across the world. Participants will receive oral tablets of upadacitinib or matching placebo once daily for 52 weeks in Study 1 and Study 2. Eligible participants from Study 1 and Study 2 will receive oral tablets of upadacitinib once daily for 52 weeks in Study 3. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 63

      Key Eligibility Criteria

      Disqualifiers:Lupus Nephritis, Neuropsychiatric SLE, Overlap Syndromes, Others
      Must Be Taking:Antimalarials, Corticosteroids, Immunosuppressants

      1000 Participants Needed

      Belimumab for Lupus

      Cincinnati, Ohio
      This trial is testing a medication called belimumab, given as an injection under the skin, in children with lupus. The goal is to see if it is safe and effective by calming down their overactive immune systems. Belimumab is approved for the treatment of lupus in adults with moderate disease activity.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:5 - 17

      Key Eligibility Criteria

      Disqualifiers:Severe Nephritis, Organ Transplant, Malignancy, Others
      Must Be Taking:Corticosteroids, Immunosuppressives, Anti-malarials, NSAIDs

      25 Participants Needed

      CC-97540 for Lupus

      Cincinnati, Ohio
      The purpose of this study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at least 2 immunosuppressants.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:16+

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular, CNS Pathology, Malignancies, Others
      Must Be Taking:Glucocorticoids, Immunosuppressants

      89 Participants Needed

      Belimumab for Pediatric Lupus

      Cincinnati, Ohio
      This is a multi-center study to evaluate the safety, pharmacokinetics, and efficacy of belimumab intravenous (IV) in pediatric patients 5 to 17 years of age with active systemic lupus erythematosus
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:5 - 17

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Severe Lupus Kidney, Others
      Must Not Be Taking:Belimumab, B Cell Therapy

      93 Participants Needed

      123

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Lupus clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Lupus clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Lupus trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Lupus is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Lupus medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Lupus clinical trials?

      Most recently, we added Yoga-Based Coaching for Lupus, Inebilizumab + Blinatumomab for Lupus and CC-97540 for Lupus to the Power online platform.